Straits Times Index
3,084.08 -6.23 (-0.20%) S&P 500
4,594.63 +26.83 (+0.59%) Dow
36,245.50 +294.60 (+0.82%) Nasdaq
14,305.03 +78.83 (+0.55%) Bitcoin USD
41,721.93 +2,293.82 (+5.82%) CMC Crypto 200
860.51 +68.95 (+8.71%)
Bayer Aktiengesellschaft (BAYN.DE)
| Previous close | 31.11 |
| Open | 31.00 |
| Bid | 30.75 x 28400 |
| Ask | 30.77 x 2100 |
| Day's range | 30.72 - 31.41 |
| 52-week range | 30.22 - 65.66 |
| Volume | |
| Avg. volume | 3,528,012 |
| Market cap | 30.219B |
| Beta (5Y monthly) | 0.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.74 |
| Earnings date | 08 Nov 2023 |
| Forward dividend & yield | 2.40 (7.71%) |
| Ex-dividend date | 02 May 2023 |
| 1y target est | 51.20 |
Insider Monkey15 Countries that Produce the Most Genetically Modified Crops
In this article, we will look into the 15 countries that produce the most genetically modified crops. If you want to skip our detailed analysis, you can go directly to the 5 Countries That Produce the Most Genetically Modified Crops. In the era of scientific innovation and development in practically every field, agriculture stands at […]
- Financial Times
Bayer chief blames thin drug pipeline on ‘years of under-investment’
Bayer’s chief executive has blamed an “old chemistry mindset” and a chronic lack of investment in research by his predecessors for a thin drug pipeline that has dragged down the group’s share price. Bayer last week abandoned a trial of blood-thinner asundexian after it did not work as hoped to treat heart disease. The setback over a drug that was supposed to generate up to €5bn in annual sales at its peak caused Bayer’s already struggling stock to fall 18 per cent in a day.
- Financial Times
Bayer drug setback adds to new CEO’s problems
Halted trial of prospective blockbuster treatment follows latest US legal blow over weedkiller Roundup
